EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Clinical characteristics and five-year outcomes in a prospective Russian real-world heart failure cohort

Nana Pogosova, Tatevik Terteryan, Ashot Avagimyan, Arthur Arutyunov, Anna Popova, Natalya Vorobyeva, Irina Osipova, Radima Zhetisheva, Aza Ausheva, Rosalinda Madonna

Vascular Pharmacology · 2026-06 · 163 · 107612

DOI: 10.1016/j.vph.2026.107612 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Vascular Pharmacology, 2026-06. Verfasst von Nana Pogosova und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac Rehabilitation and Laboratory of Preventive Cardiology, National Medical Research Centre of Cardiology after Acad. E. I. Chazov…. Hauptthemen laut MEDLINE: Heart Failure. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Despite advances in therapy, data on long-term survival and temporal mortality patterns in real-world heart failure (HF) populations, particularly during the critical early period after diagnosis or clinical destabilization, remain scarce. This study aimed to analyze long-term survival and identify factors associated with mortality in a prospective Russian real-world HF cohort that is relatively underrepresented in the international registry literature. METHODS: A prospective 5-years registry study consecutively enrolled 150 patients with HF in February-May 2018. Participants underwent comprehensive assessment of clinical state, traditional cardiovascular risk factors (RF), psychosocial RF, quality of life, perception of illness, cognitive function, and treatment characteristics. Survival was analyzed using the Kaplan-Meier method, and mortality trends were assessed over time. The Cox proportional hazard model, with calculation of hazard ratio (HR) and 95% coincidence interval (CI), was used for univariate and multivariate regression analyses. RESULTS: The cohort (median age 69 years, 57% male) was elderly and multimorbid, with high prevalence of coronary artery disease (95%), hypertension (91%), and chronic kidney disease (56%). Guideline-directed medical therapy was suboptimal: while beta-blocker and diuretic use was high (87% and 79%, respectively), utilization of aldosterone antagonists and ARNI was low (40% and 0.7%, respectively). Only 32.7% received multicomponent HF therapy. The overall 5-years (0.02-5.09) survival rate was 59.9%. Approximately half (48%) of patients died in the first year, the remaining deaths occurred in 2-nd, 3-rd and 4-th years (15%, 17%, and 20%, respectively), and deaths were recorded during 5-th and 6-th years of follow-up. Kaplan-Meier survival analysis showed that left ventricular ejection fraction (LV EF) was strongly associated with 5-years survival. In patients with reduced and moderately reduced LV EF 5-years survival was significantly lower than that in those with preserved LV EF (50.0% and 45.7% versus 70.4%, respectively). No significant difference was found only when comparing the survival curves of patients with moderately reduced and reduced LV EF (chi-square = 0.014; p = 0.906). The leading cause of death was decompensation of HF (65.2%), followed by sudden cardiac death (15.2%). Multivariate analysis showed that age (HR 1.03 per 1-year increase; 95% CI 1.01-1.06; p = 0.017), weight loss >4.5 kg in 5 days in response to therapy (HR 3.49; 95% CI 1.82-6.68; p < 0.001), anemia (HR 2.83; 95% CI 1.47-5.46; p = 0.002), obstructive sleep apnea syndrome (HR 4.43; 95% CI 1.91-10.28; p = 0.001), and HF NYHA functional class IV (HR 4.79; 95% CI 1.50-15.34; p = 0.008) were independent predictors of 5-years all-cause mortality in HF patients. CONCLUSION: This study identifies a high early mortality phenotype in a real-world HF population, strongly associated with significant gaps in guideline-directed therapy. The findings underscore the urgent need for early aggressive optimization of treatment, particularly in the high-risk period following diagnosis or destabilization of HF, to improve long-term survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureHumansFemaleMaleProspective StudiesRegistriesTime FactorsAgedRussiaRisk AssessmentMiddle AgedTreatment OutcomeRisk FactorsCardiovascular AgentsQuality of LifeAged, 80 and overComorbidity

Stichwörter der Autor:innen

ComorbidityHeart failureMortalityOutcomePrognosis

Substanzen

Cardiovascular Agents

Autor:innen und Institutionen

  • Department of Cardiac Rehabilitation and Laboratory of Preventive Cardiology, National Medical Research Centre of Cardiology after Acad. E. I. Chazov, Moscow, Russia; Department of Evidence Based Medicine, P. Lumumba Pe…
  • Department of Internal Diseases Propaedeutics, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia.
  • Department of Cardiac Rehabilitation and Laboratory of Preventive Cardiology, National Medical Research Centre of Cardiology after Acad. E. I. Chazov, Moscow, Russia.
  • Laboratory for Study of Geroprotectors and Clinical Trials, Russian Gerontology Clinical and Research Center, Pirogov Russian National Research Medical University, Moscow, Russia.
  • Department of Facultative Therapy and Occupational Diseases, Altay State Medical University, Barnaul, Russia.
  • Head of the Cardiovascular Diseases Institute, and Residency/Specialty Program, Department of Pathology, University of Pisa, Pisa, Italy.

Zitieren

APA

Pogosova, N., Terteryan, T., Avagimyan, A., Arutyunov, A., Popova, A., Vorobyeva, N., Osipova, I., Zhetisheva, R., Ausheva, A., & Madonna, R. (2026). Clinical characteristics and five-year outcomes in a prospective Russian real-world heart failure cohort. Vascular Pharmacology, 163, 107612. https://doi.org/10.1016/j.vph.2026.107612

Vancouver

Pogosova N, Terteryan T, Avagimyan A, Arutyunov A, Popova A, Vorobyeva N, et al. Clinical characteristics and five-year outcomes in a prospective Russian real-world heart failure cohort. Vascular Pharmacology. 2026;163:107612. doi:10.1016/j.vph.2026.107612

BibTeX
@article{Pogosova2026,
  author = {Pogosova, Nana and Terteryan, Tatevik and Avagimyan, Ashot and Arutyunov, Arthur and Popova, Anna and Vorobyeva, Natalya and Osipova, Irina and Zhetisheva, Radima and Ausheva, Aza and Madonna, Rosalinda},
  title = {Clinical characteristics and five-year outcomes in a prospective Russian real-world heart failure cohort},
  journal = {Vascular Pharmacology},
  year = {2026},
  volume = {163},
  pages = {107612},
  doi = {10.1016/j.vph.2026.107612}
}
Kostenlos starten →